Cargando…

Blood donor biobank and HLA imputation as a resource for HLA homozygous cells for therapeutic and research use

BACKGROUND: Allogeneic therapeutic cells may be rejected if they express HLA alleles not found in the recipient. As finding cell donors with a full HLA match to a recipient requires vast donor pools, the use of HLA homozygous cells has been suggested as an alternative. HLA homozygous cells should be...

Descripción completa

Detalles Bibliográficos
Autores principales: Clancy, Jonna, Hyvärinen, Kati, Ritari, Jarmo, Wahlfors, Tiina, Partanen, Jukka, Koskela, Satu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549658/
https://www.ncbi.nlm.nih.gov/pubmed/36210465
http://dx.doi.org/10.1186/s13287-022-03182-7
_version_ 1784805720277909504
author Clancy, Jonna
Hyvärinen, Kati
Ritari, Jarmo
Wahlfors, Tiina
Partanen, Jukka
Koskela, Satu
author_facet Clancy, Jonna
Hyvärinen, Kati
Ritari, Jarmo
Wahlfors, Tiina
Partanen, Jukka
Koskela, Satu
author_sort Clancy, Jonna
collection PubMed
description BACKGROUND: Allogeneic therapeutic cells may be rejected if they express HLA alleles not found in the recipient. As finding cell donors with a full HLA match to a recipient requires vast donor pools, the use of HLA homozygous cells has been suggested as an alternative. HLA homozygous cells should be well tolerated by those who carry at least one copy of donor HLA alleles. HLA-A-B homozygotes could be valuable for HLA-matched thrombocyte products. We evaluated the feasibility of blood donor biobank and HLA imputation for the identification of potential cell donors homozygous for HLA alleles. METHODS: We imputed HLA-A, -B, -C, -DRB1, -DQA1, -DQB1 and -DPB1 alleles from genotypes of 20,737 Finnish blood donors in the Blood Service Biobank. We confirmed homozygosity by sequencing HLA alleles in 30 samples and by examining 36,161 MHC-located polymorphic DNA markers. RESULTS: Three hundred and seventeen individuals (1.5%), representing 41 different haplotypes, were found to be homozygous for HLA-A, -B, -C, -DRB1, -DQA1 and -DQB1 alleles. Ten most frequent haplotypes homozygous for HLA-A to -DQB1 were HLA-compatible with 49.5%, and three most frequent homozygotes to 30.4% of the Finnish population. Ten most frequent HLA-A-B homozygotes were compatible with 75.3%, and three most frequent haplotypes to 42.6% of the Finnish population. HLA homozygotes had a low level of heterozygosity in MHC-located DNA markers, in particular in HLA haplotypes enriched in Finland. CONCLUSIONS: The present study shows that HLA imputation in a blood donor biobank of reasonable size can be used to identify HLA homozygous blood donors suitable for cell therapy, HLA-typed thrombocytes and research. The homozygotes were HLA-compatible with a large fraction of the Finnish population. Regular blood donors reported to have positive attitude to research donation appear a good option for these purposes. Differences in population frequencies of HLA haplotypes emphasize the need for population-specific collections of HLA homozygous samples. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13287-022-03182-7.
format Online
Article
Text
id pubmed-9549658
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-95496582022-10-11 Blood donor biobank and HLA imputation as a resource for HLA homozygous cells for therapeutic and research use Clancy, Jonna Hyvärinen, Kati Ritari, Jarmo Wahlfors, Tiina Partanen, Jukka Koskela, Satu Stem Cell Res Ther Research BACKGROUND: Allogeneic therapeutic cells may be rejected if they express HLA alleles not found in the recipient. As finding cell donors with a full HLA match to a recipient requires vast donor pools, the use of HLA homozygous cells has been suggested as an alternative. HLA homozygous cells should be well tolerated by those who carry at least one copy of donor HLA alleles. HLA-A-B homozygotes could be valuable for HLA-matched thrombocyte products. We evaluated the feasibility of blood donor biobank and HLA imputation for the identification of potential cell donors homozygous for HLA alleles. METHODS: We imputed HLA-A, -B, -C, -DRB1, -DQA1, -DQB1 and -DPB1 alleles from genotypes of 20,737 Finnish blood donors in the Blood Service Biobank. We confirmed homozygosity by sequencing HLA alleles in 30 samples and by examining 36,161 MHC-located polymorphic DNA markers. RESULTS: Three hundred and seventeen individuals (1.5%), representing 41 different haplotypes, were found to be homozygous for HLA-A, -B, -C, -DRB1, -DQA1 and -DQB1 alleles. Ten most frequent haplotypes homozygous for HLA-A to -DQB1 were HLA-compatible with 49.5%, and three most frequent homozygotes to 30.4% of the Finnish population. Ten most frequent HLA-A-B homozygotes were compatible with 75.3%, and three most frequent haplotypes to 42.6% of the Finnish population. HLA homozygotes had a low level of heterozygosity in MHC-located DNA markers, in particular in HLA haplotypes enriched in Finland. CONCLUSIONS: The present study shows that HLA imputation in a blood donor biobank of reasonable size can be used to identify HLA homozygous blood donors suitable for cell therapy, HLA-typed thrombocytes and research. The homozygotes were HLA-compatible with a large fraction of the Finnish population. Regular blood donors reported to have positive attitude to research donation appear a good option for these purposes. Differences in population frequencies of HLA haplotypes emphasize the need for population-specific collections of HLA homozygous samples. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13287-022-03182-7. BioMed Central 2022-10-09 /pmc/articles/PMC9549658/ /pubmed/36210465 http://dx.doi.org/10.1186/s13287-022-03182-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Clancy, Jonna
Hyvärinen, Kati
Ritari, Jarmo
Wahlfors, Tiina
Partanen, Jukka
Koskela, Satu
Blood donor biobank and HLA imputation as a resource for HLA homozygous cells for therapeutic and research use
title Blood donor biobank and HLA imputation as a resource for HLA homozygous cells for therapeutic and research use
title_full Blood donor biobank and HLA imputation as a resource for HLA homozygous cells for therapeutic and research use
title_fullStr Blood donor biobank and HLA imputation as a resource for HLA homozygous cells for therapeutic and research use
title_full_unstemmed Blood donor biobank and HLA imputation as a resource for HLA homozygous cells for therapeutic and research use
title_short Blood donor biobank and HLA imputation as a resource for HLA homozygous cells for therapeutic and research use
title_sort blood donor biobank and hla imputation as a resource for hla homozygous cells for therapeutic and research use
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549658/
https://www.ncbi.nlm.nih.gov/pubmed/36210465
http://dx.doi.org/10.1186/s13287-022-03182-7
work_keys_str_mv AT clancyjonna blooddonorbiobankandhlaimputationasaresourceforhlahomozygouscellsfortherapeuticandresearchuse
AT hyvarinenkati blooddonorbiobankandhlaimputationasaresourceforhlahomozygouscellsfortherapeuticandresearchuse
AT ritarijarmo blooddonorbiobankandhlaimputationasaresourceforhlahomozygouscellsfortherapeuticandresearchuse
AT wahlforstiina blooddonorbiobankandhlaimputationasaresourceforhlahomozygouscellsfortherapeuticandresearchuse
AT partanenjukka blooddonorbiobankandhlaimputationasaresourceforhlahomozygouscellsfortherapeuticandresearchuse
AT koskelasatu blooddonorbiobankandhlaimputationasaresourceforhlahomozygouscellsfortherapeuticandresearchuse